Article
Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Gastroenterology - 1 Nov 2014
Berger Carola, Romero-Brey Inés, Radujkovic Danijela, Terreux Raphael, Zayas Margarita, Paul David, Harak Christian, Hoppe Simone, Gao Min, Penin Francois, Lohmann Volker, Bartenschlager Ralf
Abstract excerpt
BACKGROUND & AIMS: Direct-acting antivirals that target nonstructural protein 5A (NS5A), such as daclatasvir, have high potency against the hepatitis C virus (HCV). They are promising clinical candidates, yet little is known about their antiviral mechanisms. We investigated the mechanisms of daclatasvir derivatives. METHODS: We used a combination of biochemical assays, in silico docking models, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.